Papillon Study
About NSCLC &
Biomarkers
About NSCLC
About Biomarkers
Understanding Biomarkers Why Get Tested FAQs
About Clinical
Research Studies
Understanding Clinical Research Why Participate FAQs
Current Clinical
Research Studies
Current Studies
Chrysalis Study Mariposa 2 Study Papillon Study
Study Locations
Participating Countries
For Healthcare
Providers
For Caregivers &
Loved Ones
Additional
Resources
NSCLC Support Janssen Oncology Research
EN-US
ES-US EN-AU
See If You Are Eligible
1-855-218-4395

About The
Papillon Study

The PAPILLON Study is evaluating the safety and effectiveness of an investigational medication in combination with chemotherapy in adults with advanced or metastatic non-small-cell lung cancer (NSCLC), who also have a gene mutation called EGFR Exon 20 insertion.

See If You Are Eligible

You may be able to take part in the PAPILLON Study if you:

  • Are 18 years or older
  • Have been diagnosed with advanced or metastatic NSCLC and have a gene mutation called EGFR Exon 20 insertion
  • Have not received any prior treatment for your advanced cancer (with the exception of prior tyrosine kinase inhibitor (TKI) therapy for a maximum of eight weeks, with documented lack of response)
  • Are either fully active and able to carry on all physical activities, or are restricted only in strenuous activity, but can walk around and carry out light housework or office work 1
Additional eligibility criteria will be assessed by the study doctor or staff.

See If You Are Eligible

For additional information:

Download the PAPILLON Study brochure
What’s involved with study participation?

Participants in the PAPILLON Study will be randomly assigned to take either the investigational study medication with chemotherapy, or chemotherapy alone while completing various study tests and procedures.

  • Chemotherapy is a standard of care treatment for NSCLC
  • The study duration will vary from person to person depending on the response to investigational medication. Investigational medication dosing and/or chemotherapy will take place on Day 1 of each study medication cycle. Each cycle will last 21 days.
  • Participants may leave the study at any point in time
Does participating in this study cost me anything?

All study required visits, tests, and medications will be provided at no cost to qualified participants. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine.

In addition, reimbursement for study-required travel, meals, and parking may be available.

If pre-qualified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

  • Learn more about the PAPILLON Study. You’ll be speaking with a study doctor to learn more regarding your participation in this study.
  • Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.
  • Determine if the PAPILLON Study may be right for you. After speaking with the study doctor and learning the details about this study, the study staff will perform a series of screening tests to determine if you are eligible to participate. If you are eligible, you and your doctor can then decide if this study is right for you. No tests for the actual study will be given at this time. If you choose to participate, the study staff will ask you to review and sign a consent form.
What can I expect if I join the study?
  • Participants in the study will be randomly (by chance) assigned to one of two treatment arms. This means you may receive the combination of the investigational medication and chemotherapy or chemotherapy alone.
  • Both you and the study staff will know which treatment arm you are receiving.
  • The investigational medication and/or chemotherapy will both be administered through intravenous infusions on Day 1 of each investigational medication cycle. Each cycle will last 21 days.
  • If you are in the group receiving chemotherapy alone, and your disease worsens, you will have the option to receive the investigational medication as well.
What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, your study doctor will ask you to come to the study clinic to determine disease progression. If your disease is progressing, you will be asked to complete an end of treatment visit 30 days after your last dose of investigational medication. You will then enter the follow-up phase with visits to the study clinic or telephone contact every 12 weeks until the end of study to find out how you are doing, if you have had any side effects, and if you have started any new cancer treatments.

Where are the study clinics located?

There are study clinics located throughout the United States. Find a location near you.

To see a list of participating study clinics in over 20 countries globally, visit this page.

For additional information:

Download the PAPILLON Study brochure
Consider enrolling in this study today.
See If You Are Eligible

SOURCE:

1ecog-acrin.org/resources/ecog-performance-status
If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path.

The more we learn, the farther we can go.